This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Louis Lasagna, MD
The University of Rochester School of Medicine and Dentistry Rochester, NY

JAMA. 1975;232(9):906.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

I should like to respond to Goldberg's rebuttal (232:143, 1975) to our commentary, "The FDA, Politics, and the Public" (232:141, 1975). To begin with, Wardell and I are certainly not arguing that the Food and Drug Administration (FDA) should approve labeling for uses of new drugs as soon as these uses gain acceptance in current medical practice and in the literature. As Goldberg recognizes in some of the quotations attributed to me, I do not believe that there is a necessary relationship between actual and optimal clinical usage. Where Goldberg and I disagree, however, is in regard to what is "substantial evidence," who is to decide what is substantial evidence, and whether such substantial evidence exists for the use of propranolol in anginal patients.

Distinguished and experienced clinicians all over the world have been impressed not only by the available literature on the use of propranolol in . . . [Full Text PDF of this Article]

Footnotes
Edited by John D. Archer, MD, Senior Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?